Medical Tidbits,Seqirus receives FDA approval for FLUAD™ (Influenza Vaccine, Adjuvanted) for adults aged 65 years and older 

research in medical field

CAMBRIDGE, Mass., Nov. 25, 2015 /PRNewswire/ — Seqirus announced today that the US Food and Drug Administration (FDA) has approved Fluad (Influenza Vaccine, Adjuvanted) to help protect those aged 65 years and older against seasonal influenza. Fluad is the first adjuvanted seasonal influenza vaccine approved in the United States; it was specifically developed for the adult population aged 65 and older.1

Fluad is an inactivated influenza vaccine indicated for active immunization of adults aged 65 and older caused by influenza virus subtypes A and B contained in the vaccine.2 read more

Trialbee is a Winner of the 2015 Red Herring Top 100 Global  

Red Herring’s Top 100 Global list has become a mark of distinction for identifying promising new companies and entrepreneurs. Red Herring editors were among the first to recognize that companies such as Facebook, Twitter, Google, Yahoo, Skype, Salesforce.com, YouTube, and eBay would change the way we live and work.

Trialbee, founded in 2010, has developed a patient centered approach and a cloud based technical platform enabling fast and efficient e-recruitment of patients to clinical trials. Trialbee thereby helps pharmaceutical companies shorten the recruitment timelines as well as bring more motivated and eligible participants to the clinical trial programs. Trialbee aims to become a market leader for e-recruitment solutions in Europe and the US and strives to become the leading provider of innovative patient centered clinical trial management software solutions by 2017.  Trialbee also received the Red Herring Top 100 Europe Award 2

To learn more about Trialbee please visit http://www.trialbee.com

Mallinckrodt Completes Sale Of Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million  

CHESTERFIELD, United Kingdom, Nov. 27, 2015 /PRNewswire/– Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, announced today that it has closed the sale of its global contrast media and delivery systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in a transaction valued at approximately $270 million. The company’s CMDS operations encompassed four manufacturing facilities and a total of approximately 1,000 employees spread across the globe, including nearly 75 in the St. Louis area. This entire workforce and the manufacturing facilities have been transferred to Guerbet. read more

Canada’s innovative pharmaceutical companies share insights at Ontario’s roundtable on national pharmacare  

OTTAWA, Nov. 27, 2015 /CNW/ – Today, members of Canada’s Research-Based Pharmaceutical Companies (Rx&D) met with the Ontario government to provide informed insights at a roundtable on national pharmacare.

“We’re pleased that the government of Ontario continues to open the lines of discussion with our industry and we look forward to further dialogue about our common goal, which is to ensure Canadians have access to the medicines they need,” said Michael Tremblay, Chair of Rx&D’s Board of Directors and President of Astellas Pharma Canada, Inc. “The ability to pay should not be a barrier. New medicines and vaccines improve the health and quality of life for patients and caregivers and they deliver significant value to governments by helping everyone avoid higher priced and more invasive interventions.”  read more

RotaWire Elite Guidewire and wireClip Torquer Guidewire by Boston Scientific: Recall – Wires May Break and Sepa: Boston Scientific Corp is recalling RotaWire ‘Elite’ core wires because they may crack and separate from the rest of the Rotablator Rotational Atheroctomy System and cause serious injury such as tamponade (blood in the sac around the heart causing decreased heart function), myocardial infarction (heart attack), and migration of wire fragments elsewhere in the body. The company has received three reports of this issue occurring, including one patient death following medical intervention to remove the broken wire. Other interventions have included purposefully blocking off (occluding) the affected artery, placing stents into the affected artery, and emergency heart surgery.

The use of affected product may cause serious adverse health consequences, including death.

BACKGROUND: The RotaWire Elite Guidewire and wireClip Torquer Guidewire are components of the Rotablator Rotational Atherectomy System. The device is used to open narrowed arteries and improve blood flow to the heart by cutting plaque from the artery wall (atherectomy).

Osiris Therapeutics to Present at the 27th Annual Piper Jaffray Healthcare Conference

COLUMBIA, Md.–(BUSINESS WIRE)–Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:30 a.m. ET in New York City.  read more

Cell Therapy Catapult Signs Memorandum of Understanding with Kanagawa Prefecture, Japan

LONDON–(EON: Enhanced Online News)–The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the signing of a memorandum of understanding with the Kanagawa Prefecture of Japan. The agreement was signed between Kuroiwa Yuji, Governor of the Kanagawa Prefecture, and Keith Thompson, the CEO of the Cell Therapy Catapult. read more

 

 

 

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

 

 

 

 

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.